ranolazine has been researched along with cardiovascular agents in 120 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.83) | 18.2507 |
| 2000's | 30 (25.00) | 29.6817 |
| 2010's | 78 (65.00) | 24.3611 |
| 2020's | 11 (9.17) | 2.80 |
| Authors | Studies |
|---|---|
| Allely, MC; Alps, BJ | 1 |
| Maisch, B; Rupp, H; Zarain-Herzberg, A | 1 |
| Hill, JA; Schofield, RS | 1 |
| Chaitman, BR; Chumakova, G; Kuch, J; Parker, JO; Pepine, CJ; Skettino, SL; Skopal, J; Wang, W; Wolff, AA | 1 |
| Berger, P | 1 |
| Frenneaux, M; Horowitz, J; Lee, L | 1 |
| Busti, AJ; Hooper, JS | 1 |
| Pechlaner, C; Wiedermann, C | 1 |
| Pauly, DF; Pepine, CJ | 1 |
| Gratsianskiĭ, NA | 1 |
| Abdallah, H; Jerling, M | 1 |
| McCullough, PA | 1 |
| Barsness, GW; Yang, EH | 1 |
| Inglis, S; Stewart, S | 1 |
| Keam, SJ; Siddiqui, MA | 1 |
| Abozguia, K; Clarke, K; Frenneaux, M; Lee, L | 1 |
| Braunwald, E; Budaj, A; Karwatowska-Prokopczuk, E; McCabe, CH; Morrow, DA; Murphy, SA; Scirica, BM; Skene, A; Varshavsky, S; Wolff, AA | 1 |
| Newby, LK; Peterson, ED | 1 |
| Melloni, C; Newby, LK | 1 |
| Chawla, PS; Kochar, MS | 1 |
| Boden, WE; Eid, F | 1 |
| Hale, SL; Kloner, RA | 1 |
| Keating, GM | 1 |
| Arora, RR; Patel, PD | 1 |
| Arcidi, JM; Belardinelli, L; Dhalla, AK; Hale, SL; Hwang, H; Kloner, RA; Shryock, JC; Simkhovich, BZ | 1 |
| Braunwald, E; Chaitman, BR; Karwatowska-Prokopczuk, E; McCabe, CH; McGuire, DK; Morrow, DA; Murphy, SA; Scirica, BM | 1 |
| Coppola, JT; Deshmukh, SH; Hermance, EV; Infantino, MN; Mindrescu, C; Patel, SR; Pinassi, E; Staniloae, CS | 1 |
| Gong, S; Guan, T; Li, Y; Sun, H; Wu, X; Yao, Z | 1 |
| Belardinelli, L; Blackburn, B; Heo, J; Iskandrian, AE; Venkataraman, R | 1 |
| Klocke, FJ | 1 |
| Aslam, S; Gray, D | 1 |
| Chirkov, YY; Horowitz, JD; Kennedy, JA; Sverdlov, AL | 1 |
| Battler, A; Dvir, D | 1 |
| D'Amico, AV; Goldhaber, SZ | 1 |
| Belardinelli, L; Hasenfuss, G; Jacobshagen, C; Maier, LS | 1 |
| Bairey Merz, CN; Berman, DS; Gill, E; Goykhman, P; Mehta, PK; Minissian, M; Shaw, LJ; Shufelt, C; Slivka, M; Slomka, PJ; Thomson, LE; Wei, J; Yang, Y | 1 |
| Carbajal, EV; Deedwania, PC | 1 |
| Athauda-Arachchi, P; Lang, C | 1 |
| Melloni, C; Newby, LK; Truffa, AA | 1 |
| Maier, LS; Sossalla, S | 1 |
| Cecchi, F; Coppini, R; Ferrantini, C; Girolami, F; Olivotto, I; Rossi, A; Tomberli, B | 1 |
| Maier, LS | 1 |
| Belardinelli, L; Cheng, ML; Karwatowska-Prokopczuk, E; Schwartz, PJ; Wang, W; Zeng, D | 1 |
| Rumsfeld, JS | 1 |
| Jacobshagen, C | 1 |
| Astarita, C; Capuano, N; Caruso, A; Cirillo, T; Marinelli, U; Quaranta, G; Rigo, F; Romano, C; Tagliamonte, E | 1 |
| Khazraei, H; Mirkhani, H; Shafa, M | 1 |
| Batatinha, JA; Belardinelli, L; Bonatti, R; Liu, G; Nearing, BD; Rajamani, S; Silva, AF; Verrier, RL; Zeng, D | 1 |
| DeLosSantos, M; Hammond, DA; Jankowski, CA; Kraemer, D; Osian, O; Smotherman, C; Tan, S | 1 |
| Daniels, JD; Hill, JA | 1 |
| Bonaca, MP; Braunwald, E; Conrad, MJ; Jarolim, P; Morrow, DA; Murphy, SA; O'Malley, RG; Sabatine, MS | 1 |
| Castriota, F; Cremonesi, A; De Luca, G; Fattori, R; Lupi, A; Marino, PN; Mirabella, F; Parisi, R; Rognoni, A; Secco, GG | 1 |
| Bacchni, S; Bongo, AS; Cavallino, C; Facchini, M; Lupi, A; Rametta, F; Rognoni, A; Rosso, R; Veia, A | 1 |
| Cattaneo, M; Gallino, A; Porretta, AP | 1 |
| Alberto Maggi, C; Boriani, G; Camm, AJ; Darius, H; De Ferrari, GM; Dusi, V; Giannelli, S; Gronda, E; Guillamón Torán, L; Leschke, M; Maier, LS; Marchionni, N; Melani, L; Mont, L; Quintana Rendón, M; Savelieva, I; Schumacher, K; Schwartz, PJ; Simonis, G; Tonini, G | 1 |
| Amaral, N; Okonko, DO | 1 |
| Dixit, D; Kimborowicz, K | 1 |
| Akil, N; Bottei, E; Kamath, S | 1 |
| Rognoni, A | 1 |
| Ghushchyan, V; Hartsfield, CL; Koch, BR; Nair, KV; Page, RL; Read, RA | 1 |
| Arnold, SV; Belardinelli, L; Chaitman, BR; Inzucchi, SE; Kosiborod, M; McGuire, DK; Spertus, JA; Tang, F; Yue, P | 1 |
| Coleman, CI; Freemantle, N; Kohn, CG | 1 |
| Alexander, KP; Anstrom, KJ; Ben-Yehuda, O; Davidson-Ray, L; Farzaneh-Far, R; James, S; Mark, DB; Mulkay, AJ; Ohman, EM; Osmukhina, A; Prather, K; Stone, GW; Weisz, G; Witkowski, A | 1 |
| Grelck, K; Rosen, L; Stewart, N; Sukal, S | 1 |
| Gourzoulidis, G; Kanakakis, J; Kourlaba, G; Maniadakis, N; Parissis, J; Vlachopoulos, C | 1 |
| Guo, J; Im, K; Morrow, DA; Patel, RB; Scirica, BM; Tannenbaum, S; Viana-Tejedor, A | 1 |
| Afthonidis, D; Alexopoulos, D; Barbetseas, J; Kelembekoglou, P; Kochiadakis, G; Limberi, S; Spanos, A; Triantafyllidis, G | 1 |
| Ambrosio, G; Grant, PJ; Tamargo, J | 1 |
| Cacciapuoti, F | 1 |
| Rayner-Hartley, E; Sedlak, T | 1 |
| Kourlaba, G; Maniadakis, N; Vardas, P; Vellopoulou, K | 1 |
| Chatzizisis, YS; Giannoglou, GD; Giannopoulos, AA | 1 |
| Colombo, A; Fragasso, G; Fumero, A; Giannini, F; Godino, C; Maranta, F; Margonato, A; Oppizzi, M; Slavich, M | 1 |
| Belardinelli, L; Braun, I; Danner, BC; Dobrev, D; Fischer, TH; Frey, N; Gummert, J; Hartmann, N; Hasenfuss, G; Maier, LS; Mason, FE; Pabel, S; Renner, A; Schotola, H; Sossalla, S; Voigt, N | 1 |
| Allard, M; Ben-Yehuda, O; Berg, J; Gottwald, M; Jochelson, P; Juan, A; Pannacciulli, N; Shao, Y; Zack, J; Zhang, H | 1 |
| Berrino, L; Cappetta, D; Ciuffreda, LP; De Angelis, A; Donniacuo, M; Esposito, G; Ferraiolo, FA; Piegari, E; Rinaldi, B; Rivellino, A; Rossi, F; Russo, R; Urbanek, K | 1 |
| Battaglia, D; Caminiti, G; Fossati, C; Massaro, R; Rosano, G; Volterrani, M | 1 |
| Rosano, GMC; Vitale, C; Volterrani, M | 1 |
| Farber, HW; Finch, KT; Stratton, EA | 1 |
| Giovannelli, L; Mannina, P; Muschert, S; Pattarino, F; Segale, L | 1 |
| Gentry, JL; Hurdle, M; Mentz, RJ; Wang, A | 1 |
| Heggermont, WA; Heymans, S; Papageorgiou, AP; van Bilsen, M | 1 |
| Barbarossa, A; Belardinelli, L; Capucci, A; Guerra, F; Romandini, A | 1 |
| Bairey Merz, CN; Berman, DS; Cook-Wiens, G; Handberg, EM; Li, D; Mehta, PK; Nelson, MD; Pepine, CJ; Sharif, B; Shaw, JL; Shufelt, C; Thompson, RB; Thomson, LEJ; Wei, J | 1 |
| Vitaliivna Kuzminova, N; Yuriivna Osovska, N | 1 |
| Davis, MK; Ignaszewski, A; Toma, M; Yeung, DF | 1 |
| Basilio Flores, JE; Loza Munárriz, C; Mejia Dolores, JW; Rey Rodriguez, DE; Salazar, CA; Veramendi Espinoza, LE | 1 |
| Alexander, KP; Anstrom, KJ; Ben-Yehuda, O; Fanaroff, AC; James, SK; Mark, DB; Ohman, EM; Prather, K; Stone, GW; Weisz, G | 1 |
| Ariano, C; Cioppa, C; De Vecchis, R; Giasi, A | 1 |
| Ahmed, B; Clegg, S; Mondragon, J; Sheldon, M | 1 |
| Cheezum, MK; Di Carli, M; Evaristo, E; Foster, C; Hainer, J; Nearing, BD; Shah, NR; Stocco, FG; Verrier, RL | 1 |
| Bögeholz, N; Dechering, DG; Eckardt, L; Fehr, M; Frommeyer, G; Kochhäuser, S; Sterneberg, M | 1 |
| Arnold, WD; Bartlett, A; Hawash, AA; Kissel, JT; Kline, D; Novak, KR; Rich, MM; Sanderson, A | 1 |
| Branstetter, J; Gilbert, BW; Huffman, J; Little, L; Meister, A; Sherard, M | 1 |
| Graham, MM; Pearson, GJ; Turgeon, RD | 1 |
| Balla, C; Ferrari, R; Pavasini, R | 1 |
| Aktas, MK; Alexis, JD; Ayala-Parades, F; Baranchuk, A; Beck, CA; Brown, MW; Daubert, JP; Dubuc, M; Feng, C; Haigney, M; Huang, DT; Mazur, A; McNitt, S; McPherson, CA; Mitchell, LB; Moss, AJ; Natale, A; Oakes, D; Piccini, JP; Pyykkonen, K; Raitt, M; Rashtian, MY; Schuger, C; Winters, S; Worley, SJ; Zareba, W; Ziv, O | 1 |
| Arnold, SV; Breeding, T; Gosch, KL; Jones, PG; Patel, KK; Peri-Okonny, PA; Spertus, JA | 1 |
| Coleman, CI; Kohn, CG; Nguyen, E; Weeda, ER | 1 |
| Bress, AP; Crook, J; Dodson, JA; Greene, T; King, JB; Knippenberg, K; LaFleur, J; Munger, MA; Nelson, RE; Radwanski, P; Reese, T; Sauer, BC; Weintraub, WS | 1 |
| Bulnes, JF; Sanfuentes, B | 1 |
| Alsina, KM; Chen, C; Duan, Q; He, M; Li, X; Ni, L; Nie, J; Wang, B; Wang, DW; Wehrens, XHT; Wen, Z; Wu, L; Zhou, C | 1 |
| Eworuke, E; Maro, JC; Tobenkin, A; Welch, EC | 1 |
| Bleske, BE; Eyler, RF; Heung, M; Mueller, BA; Salama, NN; Scoville, BA; Segal, JH | 1 |
| Gosch, K; Grantham, JA; Karmpaliotis, D; Kirtane, A; Lombardi, W; Moses, J; Nicholson, W; Peri-Okonny, PA; Salisbury, AC; Sapontis, J; Spertus, JA | 1 |
| Annibali, O; Armento, G; Calabrese, V; Greco, C; Marchesi, F; Menna, P; Minotti, G; Reggiardo, G; Salvatorelli, E | 1 |
| Arnold, SV; Cohen, DJ; Grantham, JA; Hirai, T; Jones, P; Karmpaliotis, D; Lombardi, W; Moses, J; Nicholson, WJ; Patterson, C; Qintar, M; Salisbury, AC; Sapontis, J; Sheehy, J; Spertus, JA; Tang, Y | 1 |
| Chen, T; Fang, X; Huang, J; Xu, X; Zhao, Q; Zheng, J; Zhu, H | 1 |
| He, XN; Li, H; Wang, GT; Yu, ZQ | 1 |
| Arndt, TL; Bennett, NM; Garberich, RF; Henry, TD; Schmidt, CW; Storey, KM; Traverse, JH; Wang, J | 1 |
| Bai, Y; Chen, X; Dong, C; Jiang, Y; Jiao, J; Liu, X; Qin, Y; Qu, H; Ren, L; Sun, X; Wang, S; Yang, B | 1 |
| Chang, GJ; Chang, PC; Chou, CC; Chu, Y; Lee, HL; Liu, HT; Wen, MS; Wo, HT; Yen, TH | 1 |
| Brilakis, E; Burnett, GM; Chaudhry, S; Corban, M; Eshtehardi, P; Gupta, S; Hosseini, H; Hung, OY; Koh, JS; Kumar, A; Kumar, S; Liu, C; Mehta, PK; Quyyumi, AA; Raad, M; Rabah, R; Sabbak, N; Samady, H | 1 |
| Patatanian, E; Sharp, RP; Sirajuddin, R | 1 |
| Al-Lamee, R; Davies, JR; Foley, M; Francis, DP; Ganesananthan, S; Gerber, R; Howard, J; Keeble, TR; Malik, IS; Nijjer, S; Nowbar, AN; O'Kane, P; Petraco, R; Rajkumar, CA; Seligman, H; Sen, S; Sharp, ASP; Shun-Shin, M; Tang, KH | 1 |
| Tolunay, H | 1 |
| Furtado, JD; Guo, J; Morrow, DA; Mozaffarian, D; O'Donoghue, ML; Sabatine, MS; Scirica, BM; Zelniker, TA | 1 |
| Liewluck, T; Naddaf, E; Paul, P; Vazquez Do Campo, R | 1 |
| Binder, CJ; Ciotu, CI; Fischer, MJM; Goederle, L; Hengstenberg, C; Hohensinner, PJ; Huber, K; Kaun, C; Krivaja, Z; Krychtiuk, KA; Lenz, M; Podesser, BK; Rauscher, S; Rehberger Likozar, A; Salzmann, M; Sebestjen, M; Speidl, WS; Wojta, J | 1 |
| Cesar, LAM; Dourado, LOC; Gowdak, LHW; Grobe, SF; Moreno, CPD | 1 |
42 review(s) available for ranolazine and cardiovascular agents
| Article | Year |
|---|---|
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents | 2002 |
Role of metabolically active drugs in the management of ischemic heart disease.
Topics: Acetanilides; Animals; Cardiovascular Agents; Carnitine; Clinical Trials as Topic; Dichloroacetic Acid; Energy Metabolism; Fatty Acids; Glucose; Humans; Insulin; Myocardial Ischemia; Myocardium; Piperazines; Potassium; Ranolazine; Trimetazidine | 2001 |
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Combination; Enzyme Inhibitors; Epoxy Compounds; Glucose; Humans; Hypoglycemic Agents; Insulin; Myocardial Ischemia; Myocardium; Perhexiline; Piperazines; Potassium; Ranolazine; Trimetazidine | 2004 |
Ischemic heart disease: metabolic approaches to management.
Topics: Acetanilides; Cardiovascular Agents; Carnitine; Dichloroacetic Acid; Energy Metabolism; Humans; Myocardial Ischemia; Oxidation-Reduction; Piperazines; Ranolazine; Ribose; Trimetazidine | 2004 |
Chronic angina: new medical options for treatment.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Enzyme Inhibitors; Humans; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2005 |
Evolving treatment strategies for chronic refractory angina.
Topics: Acetanilides; Angina Pectoris; Arginine; Benzazepines; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Counterpulsation; Electric Stimulation Therapy; Humans; Ivabradine; Myocardial Revascularization; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Spinal Cord | 2006 |
Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Topics: Acetanilides; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Carnitine O-Palmitoyltransferase; Drug Monitoring; Epoxy Compounds; Fatty Acids; Half-Life; Humans; Metabolic Clearance Rate; Nurse's Role; Nursing Assessment; Patient Education as Topic; Patient Selection; Perhexiline; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2006 |
Ranolazine: a review of its use in chronic stable angina pectoris.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2006 |
Modification of myocardial substrate use as a therapy for heart failure.
Topics: Acetanilides; Adrenergic beta-Antagonists; Animals; Cardiac Output, Low; Cardiovascular Agents; Energy Metabolism; Epoxy Compounds; Fatty Acids, Nonesterified; Glycine; Heart; Humans; Myocardium; Oxygen; Perhexiline; Piperazines; Ranolazine; Trimetazidine | 2006 |
What's new in clinical pharmacology and therapeutics.
Topics: Abatacept; Acetanilides; Amides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiparkinson Agents; Antirheumatic Agents; Antiviral Agents; Apomorphine; Benzazepines; Cardiovascular Agents; Fumarates; Hepatitis B; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Hypoglycemic Agents; Immunoconjugates; Multiple Sclerosis; Natalizumab; Nucleosides; Papillomavirus Vaccines; Pharmacology, Clinical; Piperazines; Pyrazines; Pyrimidinones; Quinoxalines; Ranolazine; Sitagliptin Phosphate; Smoking Cessation; Telbivudine; Thymidine; Triazoles; Varenicline; Viral Vaccines | 2008 |
Ranolazine: a review of its use in chronic stable angina pectoris.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Delayed-Action Preparations; Humans; Piperazines; Ranolazine | 2008 |
Utility of ranolazine in chronic stable angina patients.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Diabetes Complications; Glycated Hemoglobin; Humans; Piperazines; Ranolazine; Treatment Outcome | 2008 |
Ranolazine (Ranexa) in the treatment of chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Randomized Controlled Trials as Topic; Ranolazine | 2010 |
Modulation of myocardial metabolism: an emerging therapeutic principle.
Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardial Reperfusion; Myocardium; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents | 2010 |
Conventional and novel drug therapeutics to relief myocardial ischemia.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzazepines; Calcium Channel Blockers; Cardiovascular Agents; Cardiovascular System; Coronary Artery Disease; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Nicorandil; Nitrates; Piperazines; Ranolazine | 2010 |
Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Cardiovascular Agents; Coronary Disease; Drug Therapy, Combination; Humans; Hypolipidemic Agents; Ivabradine; Myocardial Revascularization; Nitrates; Piperazines; Ranolazine; Treatment Outcome | 2011 |
Extended-release ranolazine: critical evaluation of its use in stable angina.
Topics: Acetanilides; Angina, Stable; Animals; Cardiovascular Agents; Delayed-Action Preparations; Humans; Piperazines; Quality of Life; Ranolazine; Treatment Outcome | 2011 |
Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
Topics: Acetanilides; Animals; Cardiovascular Agents; Diabetes Mellitus; Heart Diseases; Humans; Piperazines; Ranolazine | 2012 |
New treatment options for late Na current, arrhythmias, and diastolic dysfunction.
Topics: Acetanilides; Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Calcium; Cardiovascular Agents; Cations; Diastole; Enzyme Inhibitors; Heart Failure; Heart Failure, Diastolic; Humans; Myocardial Contraction; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Sodium; Sodium-Calcium Exchanger | 2012 |
[Late sodium current and calcium overload--pathogenesis and adequate treatment].
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Atrial Fibrillation; Benzazepines; Calcium; Calcium Channel Blockers; Cardiovascular Agents; Coronary Artery Disease; Electrocardiography; Endothelium, Vascular; Heart Failure, Diastolic; Humans; Hypercalcemia; Ivabradine; Myocardial Ischemia; Nitrates; Piperazines; Ranolazine; Sodium; Sodium Channels; Sodium-Calcium Exchanger | 2013 |
Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization.
Topics: Angina, Stable; Animals; Benzazepines; Cardiovascular Agents; Humans; Ivabradine; Nicorandil; Percutaneous Coronary Intervention; Ranolazine; Trimetazidine | 2015 |
New Anti-Anginal Drugs: Ranolazine.
Topics: Angina Pectoris; Animals; Cardiovascular Agents; Controlled Clinical Trials as Topic; Diastole; Humans; Ranolazine; Sodium Channel Blockers | 2015 |
Ranolazine: Drug overview and possible role in primary microvascular angina management.
Topics: Cardiovascular Agents; Disease Management; Humans; Microvascular Angina; Randomized Controlled Trials as Topic; Ranolazine | 2015 |
Metabolic abnormalities of the heart in type II diabetes.
Topics: Antioxidants; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Energy Metabolism; Fatty Acids; Glucose; Humans; Mitochondria, Heart; Myocardium; Organophosphorus Compounds; Oxidative Phosphorylation; Oxidative Stress; Perhexiline; Ranolazine; Trimetazidine; Ubiquinone | 2015 |
Pharmacologic management of chronic stable angina.
Topics: Adrenergic beta-Antagonists; Angina, Stable; Benzazepines; Calcium Channel Blockers; Cardiovascular Agents; Humans; Isosorbide Dinitrate; Ivabradine; Nicorandil; Nitroglycerin; Ranolazine; Sodium Channel Blockers; Vasodilator Agents | 2015 |
Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.
Topics: Animals; Cardiovascular Agents; Coronary Artery Disease; Diabetes Mellitus; Humans; Ranolazine; Trimetazidine; Vasodilator Agents | 2016 |
Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease.
Topics: Angina, Stable; Benzazepines; Cardiovascular Agents; Heart Rate; Humans; Ivabradine; Myocardial Ischemia; Oxygen Consumption; Ranolazine | 2016 |
Ranolazine: A Contemporary Review.
Topics: Angina, Stable; Animals; Cardiovascular Agents; Chronic Disease; Drug Interactions; Drug Labeling; Humans; Off-Label Use; Practice Guidelines as Topic; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2016 |
A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.
Topics: Angina, Stable; Cardiovascular Agents; Cost-Benefit Analysis; Humans; Ranolazine; Treatment Outcome | 2016 |
Pharmacological approaches of refractory angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Coronary Artery Disease; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nicorandil; Nitrates; Ranolazine | 2016 |
Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
Topics: Angina, Stable; Animals; Cardiovascular Agents; Humans; Ranolazine | 2016 |
Metabolic support for the heart: complementary therapy for heart failure?
Topics: Acetyl-CoA C-Acyltransferase; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Dichloroacetic Acid; Energy Metabolism; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Perhexiline; Ranolazine; Stroke Volume; Trimetazidine | 2016 |
Ranolazine for rhythm control in atrial fibrillation: A systematic review and meta-analysis.
Topics: Atrial Fibrillation; Cardiovascular Agents; Humans; Ranolazine | 2017 |
Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
Topics: Adult; Angina, Stable; Atrial Fibrillation; Bundle-Branch Block; Cardiovascular Agents; Female; Humans; Microvascular Angina; Middle Aged; Ranolazine; Treatment Outcome | 2016 |
Ranolazine for stable angina pectoris.
Topics: Angina, Stable; Cardiovascular Agents; Cause of Death; Humans; Incidence; Middle Aged; Myocardial Infarction; Quality of Life; Randomized Controlled Trials as Topic; Ranolazine | 2017 |
Antiarrhythmic effects of ranolazine used both alone for prevention of atrial fibrillation and as an add-on to intravenous amiodarone for its pharmacological cardioversion: a meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Agents; Drug Therapy, Combination; Humans; Randomized Controlled Trials as Topic; Ranolazine | 2018 |
Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus.
Topics: Adolescent; Cardiovascular Agents; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Ranolazine | 2018 |
Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Nicorandil; Nitrates; Quality of Life; Ranolazine; Vasodilator Agents | 2018 |
Treatment of Angina: Where Are We?
Topics: Adrenergic beta-Antagonists; Angina, Stable; Calcium Channel Blockers; Cardiovascular Agents; Chest Pain; Humans; Ivabradine; Nicorandil; Patient Selection; Practice Guidelines as Topic; Ranolazine; Treatment Outcome; Trimetazidine | 2018 |
Ranolazine as an additional antianginal therapy in patients with stable symptomatic coronary artery disease.
Topics: Cardiovascular Agents; Coronary Artery Disease; Databases, Factual; Humans; Randomized Controlled Trials as Topic; Ranolazine | 2018 |
Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Topics: Angina Pectoris; Cardiovascular Agents; Coronary Artery Disease; Humans; Ivabradine; Myocardial Ischemia; Nicorandil; Randomized Controlled Trials as Topic; Ranolazine; Treatment Outcome | 2019 |
Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction.
Topics: Cardiovascular Agents; Humans; Myocardial Ischemia; Ranolazine | 2021 |
25 trial(s) available for ranolazine and cardiovascular agents
| Article | Year |
|---|---|
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Topics: Acetanilides; Adrenergic beta-Antagonists; Aged; Amlodipine; Angina Pectoris; Atenolol; Calcium Channel Blockers; Cardiovascular Agents; Chronic Disease; Diltiazem; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female; Hemodynamics; Humans; Male; Middle Aged; Myocardial Ischemia; Nitroglycerin; Physical Exertion; Piperazines; Ranolazine; Survival Analysis | 2004 |
Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Topics: Acetanilides; Adolescent; Adult; Aged; Cardiovascular Agents; Cohort Studies; Dealkylation; Delayed-Action Preparations; Electrocardiography; Female; Glomerular Filtration Rate; Half-Life; Humans; Kidney Diseases; Male; Middle Aged; Piperazines; Ranolazine | 2005 |
Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Topics: Acetanilides; Aged; Angina Pectoris; Cardiovascular Agents; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Proportional Hazards Models; Ranolazine; Recurrence | 2007 |
Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Blood Glucose; Cardiovascular Agents; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hyperglycemia; Male; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Ranolazine; Recurrence | 2009 |
Ranolazine improves endothelial function in patients with stable coronary artery disease.
Topics: Acetanilides; Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hyperemia; Inflammation Mediators; Male; Manometry; Middle Aged; Piperazines; Ranolazine; Time Factors; Treatment Outcome; Vasodilation | 2009 |
A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.
Topics: Acetanilides; Aged; Angina Pectoris; Automation, Laboratory; Cardiovascular Agents; Coronary Artery Disease; Coronary Circulation; Exercise Test; Exercise Tolerance; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Perfusion Imaging; Pilot Projects; Piperazines; Ranolazine; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2009 |
Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study.
Topics: Acetanilides; Administration, Oral; Biomarkers; Cardiac Catheterization; Cardiovascular Agents; Double-Blind Method; Echocardiography, Doppler; Germany; Heart Failure, Diastolic; Humans; Infusions, Intravenous; Natriuretic Peptide, Brain; Oxygen Consumption; Peptide Fragments; Piperazines; Placebo Effect; Prospective Studies; Ranolazine; Recovery of Function; Research Design; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Pressure | 2011 |
Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
Topics: Acetanilides; Adenosine; Aged; Cardiovascular Agents; Coronary Circulation; Cross-Over Studies; Double-Blind Method; Feasibility Studies; Female; Humans; Los Angeles; Magnetic Resonance Imaging; Microvascular Angina; Middle Aged; Myocardial Ischemia; Myocardial Perfusion Imaging; Pilot Projects; Piperazines; Placebo Effect; Quality of Life; Ranolazine; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vasodilator Agents | 2011 |
Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease.
Topics: Cardiovascular Agents; Coronary Stenosis; Double-Blind Method; Echocardiography; Female; Fractional Flow Reserve, Myocardial; Humans; Male; Myocardial Ischemia; Placebo Effect; Ranolazine; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2015 |
Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Cardiovascular Agents; Cohort Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Prospective Studies; Ranolazine; Risk Factors; Sensitivity and Specificity; Troponin I | 2015 |
Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study.
Topics: Aged; Atrial Fibrillation; Cardiovascular Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Electric Countershock; Electrocardiography, Ambulatory; Female; Humans; Male; Middle Aged; Ranolazine; Secondary Prevention; Treatment Outcome | 2015 |
Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.
Topics: Aged; Angina, Stable; Blood Glucose; Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Ranolazine; Retrospective Studies | 2015 |
Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Quality of Life; Radiography; Ranolazine; Treatment Outcome | 2016 |
Serum potassium levels, cardiac arrhythmias, and mortality following non-ST-elevation myocardial infarction or unstable angina: insights from MERLIN-TIMI 36.
Topics: Aged; Angina, Unstable; Arrhythmias, Cardiac; Cardiovascular Agents; Electrocardiography; Female; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Potassium; Ranolazine | 2017 |
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
Topics: Adult; Aged; Angina Pectoris; Animals; Area Under Curve; Cardiovascular Agents; CHO Cells; Chronic Disease; Comorbidity; Cricetulus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Female; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Organic Cation Transporter 2; Polypharmacy; Ranolazine; United States | 2015 |
Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Diabetes Complications; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Ranolazine | 2017 |
Ranolazine reduces repolarization heterogeneity in symptomatic patients with diabetes and non-flow-limiting coronary artery stenosis.
Topics: Cardiovascular Agents; Coronary Stenosis; Cross-Over Studies; Diabetes Mellitus; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Ranolazine; Treatment Outcome | 2018 |
Open-label trial of ranolazine for the treatment of myotonia congenita.
Topics: Adolescent; Adult; Aged; Cardiovascular Agents; Electromyography; Female; Follow-Up Studies; Hand Strength; Humans; Male; Middle Aged; Myotonia Congenita; Pilot Projects; Ranolazine; Self Report; Severity of Illness Index; Treatment Outcome; Young Adult | 2017 |
Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
Topics: Aged; Cardiovascular Agents; Defibrillators, Implantable; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Ranolazine; Risk Factors; Tachycardia, Ventricular; Ventricular Fibrillation | 2018 |
Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
Topics: Administration, Oral; Adult; Angina, Stable; Area Under Curve; Biological Variation, Population; Cardiovascular Agents; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Pilot Projects; Prospective Studies; Ranolazine; Renal Dialysis; Tablets; Young Adult | 2019 |
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Diastole; Endpoint Determination; Female; Humans; Male; Middle Aged; Ranolazine; Safety | 2019 |
Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded, Controlled Pilot Trial.
Topics: Atherosclerosis; Cardiovascular Agents; Double-Blind Method; Fractional Flow Reserve, Myocardial; Humans; Myocardial Ischemia; Pilot Projects; Ranolazine; Treatment Outcome | 2020 |
Achieving Optimal Medical Therapy: Insights From the ORBITA Trial.
Topics: Amlodipine; Bisoprolol; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isosorbide Dinitrate; Male; Middle Aged; Nicorandil; Percutaneous Coronary Intervention; Ranolazine; Treatment Outcome; Vasodilator Agents | 2021 |
Antinociceptive effect of ranolazine and trimetazidine.
Topics: Aged; Aged, 80 and over; Analgesics; Cardiovascular Agents; Female; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2021 |
Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36.
Topics: Acute Coronary Syndrome; Biomarkers; Cardiovascular Agents; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Fatty Acids, Omega-3; Female; Humans; Incidence; Male; Middle Aged; Ranolazine; Risk Assessment; Risk Factors; United States | 2021 |
53 other study(ies) available for ranolazine and cardiovascular agents
| Article | Year |
|---|---|
Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion.
Topics: Acetanilides; Animals; Cardiovascular Agents; Coronary Disease; Creatine Kinase; L-Lactate Dehydrogenase; Male; Myocardial Reperfusion; Myocardium; Papio; Piperazines; Ranolazine | 1990 |
Ranolazine and other antianginal therapies in the era of the drug-eluting stent.
Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Drug Therapy, Combination; Humans; Myocardial Revascularization; Piperazines; Ranolazine; Risk | 2004 |
Ranolazine as add-on therapy for patients with severe chronic angina.
Topics: Acetanilides; Angina Pectoris; Antihypertensive Agents; Cardiovascular Agents; Chronic Disease; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Piperazines; Ranolazine | 2004 |
Ranolazine as add-on therapy for patients with severe chronic angina.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Piperazines; Ranolazine | 2004 |
[Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. Results of CARISA].
Topics: Acetanilides; Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Atenolol; Cardiovascular Agents; Chronic Disease; Diltiazem; Double-Blind Method; Exercise Test; Humans; Multicenter Studies as Topic; Piperazines; Placebos; Randomized Controlled Trials as Topic; Ranolazine; Time Factors; Vasodilator Agents | 2004 |
Does ranolazine have a place in the treatment of acute coronary syndromes?
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Enzyme Inhibitors; Humans; Myocardial Infarction; Piperazines; Ranolazine | 2007 |
Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Topics: Acetanilides; Acute Coronary Syndrome; Acute Disease; Angina Pectoris; Cardiovascular Agents; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Quality of Life; Randomized Controlled Trials as Topic; Ranolazine; Recurrence; Sex Factors; Thrombolytic Therapy | 2008 |
The evolving role of medical therapy for chronic stable angina.
Topics: Acetanilides; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Coronary Artery Bypass; Disease-Free Survival; Enzyme Inhibitors; Humans; Piperazines; Platelet Aggregation Inhibitors; Ranolazine; Risk Factors; Risk Reduction Behavior | 2008 |
The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit.
Topics: Acetanilides; Animals; Blood Pressure; Cardiovascular Agents; Coronary Circulation; Disease Models, Animal; Heart Rate; Male; Myocardial Infarction; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Piperazines; Rabbits; Ranolazine | 2008 |
Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application.
Topics: Acetanilides; Animals; Blood Pressure; Cardioplegic Solutions; Cardiovascular Agents; Female; Heart Arrest, Induced; Myocardial Reperfusion Injury; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley | 2009 |
Synthesis of ranolazine metabolites and their anti-myocardial ischemia activities.
Topics: Acetanilides; Animals; Cardiovascular Agents; Drug Evaluation, Preclinical; Electrocardiography; Female; Glucose; Isoproterenol; Male; Mice; Mice, Inbred Strains; Myocardial Ischemia; Oxidation-Reduction; Piperazines; Ranolazine | 2009 |
Ranolazine and the myocardial demand-supply balance.
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Coronary Artery Disease; Coronary Circulation; Exercise Test; Humans; Myocardial Ischemia; Myocardial Perfusion Imaging; Oxygen Consumption; Piperazines; Ranolazine; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2009 |
Ask the doctor. A year ago, I had an orchiectomy for prostate cancer; my PSA is now 0.74. Not long afterward, I had two cardiac stents implanted. I still have some angina and shortness of breath. I started Ranexa a couple of weeks ago, which helps my angi
Topics: Acetanilides; Angina Pectoris; Cardiovascular Agents; Health Knowledge, Attitudes, Practice; Humans; Male; Orchiectomy; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Ranolazine; Testosterone | 2010 |
Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosis.
Topics: Acetanilides; Aged, 80 and over; Angina Pectoris; Aortic Valve Stenosis; Cardiovascular Agents; Female; Humans; Mitral Valve Stenosis; Piperazines; Ranolazine; Severity of Illness Index; Treatment Outcome | 2012 |
[Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: novel perspectives for ranolazine].
Topics: Acetanilides; Adult; Cardiac Pacing, Artificial; Cardiac Surgical Procedures; Cardiomyopathy, Hypertrophic; Cardiomyopathy, Restrictive; Cardiovascular Agents; Catheter Ablation; Enzyme Inhibitors; Female; Humans; Pacemaker, Artificial; Piperazines; Ranolazine; Severity of Illness Index; Treatment Outcome | 2012 |
The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Cardiovascular Agents; Death, Sudden, Cardiac; Electrocardiography; Female; Humans; Incidence; Kaplan-Meier Estimate; Long QT Syndrome; Male; Multivariate Analysis; Piperazines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ranolazine; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2013 |
Introduction: Managing patients with chronic angina: emerging therapeutic options for improving clinical efficacy and outcomes.
Topics: Acetanilides; Angina, Stable; Cardiovascular Agents; Chronic Disease; Health Care Costs; Humans; Piperazines; Ranolazine | 2006 |
Effect of ranolazine on cardiac microcirculation in normal and diabetic rats.
Topics: Acetanilides; Animals; Blood Flow Velocity; Blood Pressure; Cardiovascular Agents; Coronary Circulation; Diabetes Mellitus, Experimental; Heart Rate; Injections, Intravenous; Laser-Doppler Flowmetry; Male; Microcirculation; Piperazines; Ranolazine; Rats; Rats, Sprague-Dawley; Time Factors | 2014 |
Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation.
Topics: Animals; Atrial Fibrillation; Benzazepines; Cardiovascular Agents; Drug Therapy, Combination; Guinea Pigs; Heart Rate; Ivabradine; Male; Ranolazine; Swine | 2015 |
Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries.
Topics: Aged; Atrial Fibrillation; Cardiac Valve Annuloplasty; Cardiovascular Agents; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Germany; Heart Valve Prosthesis Implantation; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Postoperative Period; Ranolazine; Retrospective Studies | 2015 |
Funny and late: targeting currents governing heart rate in atrial fibrillation.
Topics: Animals; Atrial Fibrillation; Benzazepines; Cardiovascular Agents; Heart Rate; Male; Ranolazine | 2015 |
Ranolazine overdose-induced seizures.
Topics: Adolescent; Cardiovascular Agents; Drug Overdose; Glasgow Coma Scale; Humans; Male; Ranolazine; Seizures; Suicide, Attempted | 2015 |
Old and New Drugs for Treatment of Stable Angina.
Topics: Adrenergic beta-Antagonists; Angina, Stable; Calcium Channel Blockers; Cardiovascular Agents; Drug Discovery; Humans; Nitrates; Ranolazine | 2015 |
Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Stable; Calcium Channel Blockers; Cardiovascular Agents; Chronic Disease; Comparative Effectiveness Research; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Health Resources; Humans; Male; Nitroglycerin; Ranolazine; Retrospective Studies; Risk Factors; Treatment Outcome; United States; Vasodilator Agents | 2015 |
Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
Topics: Aged; Angina, Stable; Cardiovascular Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Female; Humans; Male; Quality of Life; Quality-Adjusted Life Years; Ranolazine; Sodium Channel Blockers; Surveys and Questionnaires; United Kingdom | 2015 |
Acute generalized exanthematous pustulosis associated with ranolazine.
Topics: Acute Generalized Exanthematous Pustulosis; Aged, 80 and over; Cardiovascular Agents; Glucocorticoids; Humans; Male; Prednisone; Ranolazine | 2015 |
Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
Topics: Angina Pectoris; Cardiovascular Agents; Chronic Disease; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Greece; Humans; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Ranolazine; Standard of Care | 2015 |
Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
Topics: Aged; Aged, 80 and over; Angina, Stable; Cardiovascular Agents; Female; Follow-Up Studies; Greece; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Quality of Life; Ranolazine; Severity of Illness Index; Treatment Outcome | 2016 |
Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy.
Topics: Aged; Angina Pectoris; Benzazepines; Cardiovascular Agents; Echocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Ivabradine; Male; Myocardial Ischemia; Ranolazine; Retrospective Studies; Sodium Channel Blockers; Stroke Volume; Systole; Time Factors; Tomography, Emission-Computed, Single-Photon; Trimetazidine; Vasodilator Agents; Ventricular Function, Left | 2016 |
The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology.
Topics: Aged; Amiodarone; Atrial Function; Calcium; Calcium Signaling; Cardiovascular Agents; Dronedarone; Drug Therapy, Combination; Female; Heart Atria; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Contraction; Myocytes, Cardiac; Ranolazine; Sarcomeres; Ventricular Function | 2016 |
Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ranolazine; Rats; Rats, Inbred Dahl; Signal Transduction; Stroke Volume; Treatment Outcome; Ventricular Remodeling | 2016 |
Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Agents; Coronary Disease; Diabetes Mellitus, Type 2; Exercise Test; Female; Follow-Up Studies; Humans; Insulin Resistance; Male; Middle Aged; Obesity; Pilot Projects; Ranolazine | 2016 |
Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study.
Topics: Aged; Cardiovascular Agents; Female; Heart Failure; Humans; Hypertension, Pulmonary; Male; Pilot Projects; Ranolazine; Stroke Volume | 2016 |
Formulation and Coating of Alginate and Alginate-Hydroxypropylcellulose Pellets Containing Ranolazine.
Topics: Alginates; Cardiovascular Agents; Cellulose; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Drug Implants; Drug Liberation; Glucuronic Acid; Hexuronic Acids; Methacrylates; Polymers; Polymethacrylic Acids; Ranolazine | 2016 |
Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME).
Topics: Aged; Angina Pectoris; Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Dyspnea; Female; Humans; Male; Middle Aged; Pilot Projects; Ranolazine | 2016 |
Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine.
Topics: Adult; Aged; Cardiovascular Agents; Clinical Trials as Topic; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Diastole; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Microcirculation; Microvessels; Middle Aged; Myocardium; Ranolazine; Retrospective Studies; Sodium Channel Blockers; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Ranolazine for Refractory Angina in a Heart Transplant Recipient With Cardiac Allograft Vasculopathy.
Topics: Adult; Allografts; Angina Pectoris; Cardiovascular Agents; Drug Therapy, Combination; Heart Transplantation; Humans; Male; Ranolazine; Vascular Diseases | 2017 |
Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
Topics: Aged; Angina, Stable; Cardiovascular Agents; Coronary Disease; Female; Humans; Male; Microcirculation; Middle Aged; Pilot Projects; Ranolazine; Treatment Outcome | 2017 |
Comparison of vernakalant and ranolazine in atrial fibrillation.
Topics: Animals; Anisoles; Atrial Fibrillation; Cardiovascular Agents; Drug Evaluation, Preclinical; In Vitro Techniques; Pyrrolidines; Rabbits; Ranolazine | 2017 |
Low Diastolic Blood Pressure Is Associated With Angina in Patients With Chronic Coronary Artery Disease.
Topics: Age Factors; Aged; Angina Pectoris; Blood Pressure; Body Mass Index; Cardiovascular Agents; Coronary Artery Disease; Cross-Sectional Studies; Diastole; Diuretics; Female; Humans; Logistic Models; Male; Nitrates; Ranolazine; Renal Insufficiency, Chronic; Sex Factors; United States | 2018 |
Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
Topics: Angina, Stable; Cardiovascular Agents; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Humans; Male; Markov Chains; Prospective Studies; Quality of Life; Ranolazine | 2018 |
Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Stable; Calcium Channel Blockers; Cardiovascular Agents; Female; Follow-Up Studies; Health Care Costs; Humans; Male; Ranolazine; Retrospective Studies; Time Factors; Treatment Outcome; United States; Veterans | 2018 |
Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na
Topics: Animals; Calcium; Cardiomegaly; Cardiovascular Agents; Cell Line; Fibrosis; Heart Failure; Hypertension; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Random Allocation; Ranolazine; Sodium | 2019 |
Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure.
Topics: Aged; Anticonvulsants; Cardiovascular Agents; Cohort Studies; Humans; Kidney Diseases; Logistic Models; Ranolazine; Risk Assessment; Seizures; United States; United States Food and Drug Administration | 2019 |
Physical Activity After Percutaneous Coronary Intervention for Chronic Total Occlusion and Its Association With Health Status.
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Chronic Disease; Coronary Occlusion; Exercise; Exercise Tolerance; Female; Follow-Up Studies; Health Status; Humans; Male; Middle Aged; Nitrates; Percutaneous Coronary Intervention; Ranolazine; Treatment Outcome | 2019 |
De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Agents; Chi-Square Distribution; Chronic Disease; Coronary Occlusion; Dyspnea; Female; Health Status; Health Surveys; Humans; Logistic Models; Male; Myocardial Ischemia; Nitro Compounds; Percutaneous Coronary Intervention; Prospective Studies; Quality of Life; Ranolazine; Registries; Time Factors | 2019 |
Effects of ranolazine on cardiac function in rats with heart failure.
Topics: Animals; Apoptosis; Cardiovascular Agents; Cells, Cultured; Disease Models, Animal; Heart Failure; Injections, Intraperitoneal; Male; Ranolazine; Rats; Rats, Wistar | 2019 |
Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Topics: Aged; Angina Pectoris; Cardiovascular Agents; Constipation; Deprescriptions; Diabetes Mellitus; Disease Progression; Dizziness; Drug Costs; Dyslipidemias; Edema; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Nausea; Ranolazine; Registries; Smoking; Treatment Failure; Treatment Outcome | 2020 |
Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1/NRG1 pathway.
Topics: Animals; Apoptosis; Blood Glucose; Cardiovascular Agents; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dose-Response Relationship, Drug; Male; Neuregulin-1; Ranolazine; Rats; Rats, Sprague-Dawley; Receptor, Notch1; Signal Transduction | 2020 |
Mechanisms of ranolazine pretreatment in preventing ventricular tachyarrhythmias in diabetic db/db mice with acute regional ischemia-reperfusion injury.
Topics: Action Potentials; Animals; Calcium; Calcium-Binding Proteins; Cardiovascular Agents; Diabetes Mellitus, Experimental; Female; Heart Rate; Mice; Myocardial Reperfusion Injury; Ranolazine; Tachycardia, Ventricular | 2020 |
Ranolazine-induced lipid storage myopathy presenting with respiratory failure and head drop.
Topics: Aged; Cardiovascular Agents; Humans; Lipid Metabolism, Inborn Errors; Male; Muscular Dystrophies; Ranolazine; Respiratory Insufficiency; Sodium Channel Blockers | 2021 |
Pharmacologic modulation of intracellular Na
Topics: Acute Coronary Syndrome; Animals; C-Reactive Protein; Cardiovascular Agents; Coronary Artery Disease; Endothelial Cells; Humans; Inflammation; Mice; Ranolazine; Sodium; Sodium Channel Blockers | 2022 |
Concomitant Use of Ranolazine and Trimetazidine in Patients with Refractory Angina: An Initial Experience.
Topics: Angina Pectoris; Angina, Stable; Cardiovascular Agents; Humans; Ranolazine; Treatment Outcome; Trimetazidine; Vasodilator Agents | 2022 |